B+
Bull case
25%
Probability
Target price
$48.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
FTH
Faeth TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$26.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-14
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+37.5
Score
AI commentary
Post-earnings news tone is cautiously positive because management reaffirmed the year-end PIK-201 milestone, initiated PIK-101, and reported $186.4 million of cash. However, no trusted consensus comparison, analyst revisions, or post-print market-reaction attribution was available. Social and other sentiment fields are unavailable rather than neutral. The deterministic prior remains negative, with expected returns of -8.44% over 20 days and -17.73% over 120 days, so this remains a low-coverage, event-driven monitoring view.
RankAlpha Sentiment Codex - 2026-08-14
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-04eventQ2 results reaffirm funded clinical timelineMedium impact
The Q2 release reported $186.4 million of cash, cash equivalents and marketable securities, reiterated year-end 2026 topline data for Phase 2 PIK-201, and confirmed first-patient dosing in Phase 1b/2 PIK-101. No consensus surprise was provided. [#SEC-8K-2026-08-04]
2026-12-31eventPIK-201 Phase 2 endometrial-cancer topline dataHigh impact
Topline results from the Phase 2 PIK-201 trial are expected by year-end 2026. The outcome remains binary, with efficacy and safety data unavailable in the packet. [#SEC-8K-2026-08-04]
2027-12-31catalystPIK-101 breast-cancer development readoutHigh impact
PIK-101 is in Phase 1b/2 for HR+/HER2- advanced breast cancer, with initial safety and efficacy data expected in 2027. The program expands optionality but remains early-stage. [#SEC-8K-2026-08-04]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-14 • Updated nightlySource: Internal modelMethodology